

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司

Aceso Life Science Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00474)

HIGH CONCENTRATION OF SHAREHOLDING

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in respect of the concentration of the shareholding of Aceso Life Science Group Limited (the “**Company**”) in the hands of a limited number of shareholders of the Company (the “**Shareholders**”) as at 31 December 2025.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the shares of the Company (the “Shares”) could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares.

This announcement is made at the request of the Stock Exchange in respect of the concentration of the shareholding of the Company in the hands of a limited number of Shareholders as at 31 December 2025.

HIGH CONCENTRATION OF SHAREHOLDING

The Company noted that an announcement has been published by the Securities and Futures Commission (the “SFC”) on 13 January 2026 (the “SFC Announcement”). As disclosed in the SFC Announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC’s findings suggested that, as at 31 December 2025, 20 Shareholders and their related parties held an aggregate of 1,387,094,033 Shares, representing 18.79% of the issued Shares. Such shareholding, together with 5,310,485,115 Shares (representing 71.94% of the issued Shares) held by three substantial Shareholders, represented 90.73% of the issued Shares. As such, only 684,197,657 Shares (representing 9.27% of the issued Shares) were in the hands of other Shareholders.

Based on the SFC Announcement, as at 31 December 2025, the shareholding structure of the Company was as follows:

	Number of Shares held <i>(Shares)</i>	% of total number of issued Shares <i>(%)</i>
Three substantial Shareholders	5,310,485,115	71.94
20 Shareholders and their related parties	1,387,094,033	18.79
Other Shareholders	684,197,657	9.27
Total	<u>7,381,776,805</u>	<u>100.00</u>

As stated in the SFC Announcement:

- (i) The closing price of the Shares rose from HK\$0.019 on 10 September 2025 to HK\$0.112 on 31 December 2025, representing a gain of 489%.
- (ii) On 12 January 2026, the price of the Shares closed at HK\$0.118, representing an increase of 521% from the closing price of HK\$0.019 on 10 September 2025.

The board (the “Board”) of directors (the “Director(s)”) of the Company wishes to clarify that the information above is extracted from the SFC Announcement and the Company has not independently verified such information other than the information set out in paragraphs (i) and (ii) above. Please refer to the SFC Announcement for more information.

PUBLIC FLOAT

Based on the information available and to the Directors' best knowledge after making all reasonable enquiries, the Company confirms that not less than 25% of the Company's issued Shares are in the hands of the public as at 31 December 2025 and as at the date of this announcement, the Company is able to comply with the public float requirement under the Rules Governing the Listing of Securities on the Stock Exchange.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares. Further, as a result of the high concentration of shareholding, the Company's securities may not have a genuine market or its shareholding may have been concentrated in the hands of a few Shareholders.

By order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 13 January 2026

As at the date of this announcement, the Board comprises two executive Directors, namely Dr. Zhiliang Ou (J.P. (Australia)) and Mr. Fok Chi Tak; one non-executive Director, namely Ms. Jiang Yang; and three independent non-executive Directors, namely Mr. Mak Yiu Tong, Mr. Lam Kwan Sing and Mr. Chan Ming Sun Jonathan.